



26th 50 YEARS OF EMLTD Anniversary International Congress on Thrombosis

ATHENS | JUNE
GREECE | 19-22
2019



European and Mediterranean League
against Thrombotic Diseases

MEGARON
Athens International
Conference Center



HOSTING SOCIETY

Institute for the Study and
Education on Thrombosis
and Antithrombotic Therapy

www.thrombosiscongress.org

SCIENTIFIC PROGRAM

Wednesday, 19 June 2019

12:00 – 16:00	NIKOS SKALKOTAS HALL
16:00 – 17:00	Opening Lectures
	LATE BREAKING – CLINICAL STUDIES ON ANTITHROMBOTIC THERAPY Chairs: Stavros Konstantinides (Germany) , Dimitri Richter (Greece)
17:00 – 19:00	STATE OF THE ART SESSION. Novel Antithrombotic Strategies Chairs: Alex Spyropoulos (USA) , Sam Schulman (Canada) State of the Art Lectures 1. New Anticoagulant Strategies - Jeff Weitz (Canada) 2. New Antiplatelet Strategies- Marco Cattaneo (Italy) New Frontiers in Thromboprophylaxis 1. Individualized Strategies for Venous Thromboprophylaxis in Medically Ill Patients - Alex Spyropoulos (USA) 2. Individualized Strategies for Venous Thromboprophylaxis in Surgical Patients - Juan Arcelus (Spain)
19:00 – 19:30	KEYNOTE LECTURE The tools for future cardiovascular health: imaging, genetics and behavior - Valentin Fuster (USA)
19:30	OPENING CEREMONY Chairs: Alexandros Tselepis (Greece) , Grigoris Gerotziafas (France) , Vittorio Pengo (Italy) Welcome from the President of EMLTD - Vittorio Pengo (Italy) Welcome from the President of ISETAT - Dimitri Richter (Greece) 50 years of EMLTD - Lina Badimon (Spain) Closing Remarks and Invitation to Welcome Reception – Alexandros Tselepis (Greece)

08:30 – 10:00	STATE OF THE ART SESSION. Advances in Platelet Functionality and Implication in Disease States	
	Chairs: Lina Badimon (Spain) , Efrosyni Nomikou (Greece)	
08:30 – 08:50	Platelet involvement in Tumorigenesis and Metastasis. Potential role of Aspirin and P2Y ₁₂ Receptor antagonists - Paola Patrignani (Italy)	
08:50 – 09:10	Tumor-Educated Platelets: A Potential Biomarker for Cancer Detection and Progression Monitoring - Thomas Wurdinger (The Netherlands)	
09:10 – 09:30	Platelets in Regenerative Medicine	
09:30 – 09:50	Platelet multidrug resistance protein 4 (MRP4). Role in platelet activation and a potential pharmacologic target for thrombotic diseases - Christilla Bachelot-Loza (France)	
09:50 – 10:00	Discussion	
10:00 – 11:00	Oral Presentations	
11:00 – 11:30	Coffee Break-Exhibition and Poster Presentation	
11:30 – 13:00	PLENARY SESSION	ADVANCED CLINICAL WORKSHOP
	Nikos Skalkotas Hall	Hall A
	Controversies in Antithrombotic Treatment	Improving clinical understanding and exploring practical guidance in antithrombotic therapy
	Chairs: Biljana Vuckovic (Serbia) , Grigoris Gerotziapas (France)	Interactive
	<i>Discuss clinical topics where evidence is lacking and RCTs limited</i>	Chairs: James Douketis (Canada) , Miltiadis Matsagkas (Greece)
	1. Management of vein thrombosis of rare localization - Walter Ageno (Italy)	1. Venous thrombosis in post-operative patient 2. May-Thurner syndrome variant

13:00 – 14:00

2. Antithrombotic treatment in elderly - [Pieter Kamphuisen \(The Netherlands\)](#)
3. Antithrombotic Treatment in patients in ICU: Challenges and Obstacles
4. DOACs in acquired and hereditary thromophilia: follow your heart or follow the fashion? - [Efrosyni Nomikou \(Greece\)](#)

Sponsored Educational or Satellite symposium

3. Challenging case of HIT
4. Venous thrombosis in difficult locations
5. PAD + recent bypass grafts (or angioplasty)
6. PAD + AF or CAD (need for AC and AP therapy)

Panelists: [Beverly Hunt \(UK\)](#), [Walter Ageno \(Italy\)](#), [Jeff Weitz \(Canada\)](#)

MEET THE EXPERTS SESSION. Thrombotic Microangiopathies

1. Pathophysiology, Clinical Presentation and Novel therapies in Thrombotic Thrombocytopenic Purpura. - [Flora Peyvandi \(Italy\)](#)
2. Hemolytic Uremic Syndromes: pathophysiology, presentation and treatment - [Gianluigi Ardissino \(Italy\)](#).
3. Thrombocytopenia and Hemolysis Beyond Thrombotic Thrombocytopenic Purpura and Atypical Hemolytic Uremic Syndrome - [Han-Mou Tsai \(USA\)](#)

14:00 – 15:00

Light Lunch-Exhibition and Poster Presentation
 Science at a Glance Session 1. Moderated Poster Presentations
 Selection from Submitted Abstracts

15:00 – 16:00

MEET THE EXPERTS SESSION. Perioperative Management of Antithrombotics

Chairs: [Walter Ageno \(Italy\)](#),

PLENARY SESSION: Laboratory Measurement of Platelet functionality and DOACs

1. Monitoring platelet function:

16:00 – 17:00

Sam Schulman (Canada)

1. DOACs/VKAs and elective surgery - James Douketis (Canada)
2. DOACs/VKAs and urgent surgery - Eleni Arnaoutoglou (Greece)
3. Perioperative Management of DAPT in patients with coronary stents - Thomas Thiele (Germany)

what have we learned from randomized clinical trials? -

Dimitrios Alexopoulos (Greece)

2. Platelet activation assays valuable to diagnose heparin-induced thrombocytopenia and platelet secretion disorders - François Mullier (Belgium)
3. Laboratory testing in patients treated with DOACs: a practical guide for clinicians

DEBATE. Pharmacokinetic versus Laboratory-based Management of DOACs in Procedures

PLENARY SESSION. Platelets and Thrombosis: New Hits and Leads

Chairs: Marco Cattaneo (Italy), Alex Spyropoulos (USA)

(Joint Session with EMLTD Foundation)

1. In favor of laboratory-based management. Armando D'Angelo (Italy)
2. In favor of PK-based management. James Douketis (Canada)
3. 20-25 min each presentation (including 5 min of individual discussion)
4. 10-15 min final discussion and debate.

Chairs: David Varon (Israel), Vittorio Pengo (Italy)

1. ER Stress and UPR related effects in platelets and thrombosis - Lina Badimon (Spain)
2. Oncopharmacology and thrombosis: from mechanisms to complications - Baruch Brenner (Israel)
3. Platelets in no-Reflow: Are they the culprit? - Dirk Duncker (The Netherlands)

17:00 – 17:30

Coffee Break-Exhibition and Poster Presentation
Selection from Submitted Abstracts

17:30 – 19:00

**PLENARY SESSION.
Challenges in Prevention and
Treatment of Cancer-
Associated Thrombosis**

Chairs: Grigoris Gerotziapas (France), Darko Antic (Serbia)

1. Biomarkers of hypercoagulability in personalized management of CAT - Anna Falanga (Italy)
2. RAMs for CAT prevention - Marc Carrier (Canada)
3. Practical and ethical issues in treatment of cancer associated thrombosis
4. DOACs and LMWHs : competitive of complementary strategies in prevention and treatment of CAT? - Ingrid Pabinger (Austria)

19:00 – 20:00

**Educational or Satellite
symposium**

**WORKSHOP. Thrombosis in
Women: Understanding the
Risks**

Chairs: Ali Taher (Lebanon), Dimitris Tousolis (Italy)

1. Arterial thrombosis: The risk of being woman - Teresa Padró (Spain)
2. Venous Thrombosis in women similarities and differences between sexes - Beverly Hunt (UK)
3. CAD in women: from manifestation to management - Edina Cenko (Italy)

**WORKSHOP. New Players /
Comorbidities in Thrombosis**

*(Joint session with the ESC
Thrombosis And Coronary
Pathophysiology Working Groups)*

Chairs: Joao Morais (Portugal), Teresa Padró (Spain)

1. Adipose tissue and thrombosis.
2. Periodontal Disease, infection, inflammation and Diabetes. Carlos Mendieta (Spain)
3. ISACS-Registry: Arterial thrombosis -related events in European countries in transition - Raffaele Bugiardini (Italy)

08:00 – 09:30

**PLENARY SESSION.
Thrombosis and Immunity**

Chairs: [Elmina Lefkou \(Greece\)](#)

1. Functional significance of the platelet immune receptors GPVI and CLEC-2
2. The Mutual Relation of Platelet Activation and Innate Immunity
3. Platelet-Neutrophil Interactions in Thrombo-inflammation. The effect of Antithrombotic Drugs - [Alexandros Tselepis \(Greece\)](#)

ADVANCED CLINICAL SEMINAR. Management of Oral Anticoagulants-Associated Bleeding

Chairs: [Sam Schulman \(Canada\)](#), [Elissavet Grouzi \(Greece\)](#)

1. Reversal of anti-FXa DOACs with specific antidote. Lessons from recent clinical trial - [Jeff Weitz \(Canada\)](#)
2. Specific antidote for Dabigatran. Efficacy and safety profile - [Ellias Kyriakou \(Greece\)](#)
3. Bleeding management using Prothrombin Complex Concentrates - [Sam Schulman \(Canada\)](#)

09:30 10:30

Oral Presentations

Selection from Submitted Abstracts

Oral Presentations

Selection from Submitted Abstracts

10:30 – 11:00

Coffee Break-Exhibition and Poster Presentation
Selection from Submitted Abstracts

11:00 – 13:00

**MEET THE EXPERTS SESSION.
Thrombocardiology**

Chairs: [Dimitrios Alexopoulos \(Greece\)](#)

1. Antithrombotic therapy for acute coronary syndrome: Current status and future directions - [Dimitrios Alexopoulos \(Greece\)](#)
2. Guided de-escalation of antiplatelet treatment in

ADVANCED CLINICAL WORKSHOP. Clinical Prediction Guides for Recurrent VTE

Chairs: [Jeff Weitz \(Canada\)](#), [Stavros Konstantinides \(Germany\)](#)

Part 1 (40 min): Clinical Prediction Guides for Recurrent VTE: How do we use them in everyday practice? - [Alberto Tosetto \(Italy\)](#)

	<p>ACS patients undergoing PCI - Dirk Sibbing (Germany)</p> <p>3. Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention - Davide Capodanno (Italy)</p> <p>4. DOACs in AF: Gaps still to be filled.</p> <p>5. Anticoagulation for prosthetic heart valves: unresolved questions requiring answers</p>	<p>Part 2 (50 min): Debate: most patients with unprovoked VTE need life-long anticoagulant therapy.</p> <p>Pro. - Walter Ageno (Italy) Con. - Sam Schulman (Canada)</p>
<p>13:00 – 14:00</p>	<p>Sponsored Educational or Satellite symposium.</p>	<p>PLENARY SESSION. Disseminated Intravascular Coagulation</p> <p>Chairs: Evangelos Terpos (Greece)</p> <p>1. Update in thrombotic microangiopathies - Paul Coppo (France)</p> <p>2. DIC: Hypercoagulability or inflammatory state? - Jawed Fareed (USA)</p> <p>3. New therapeutic strategies in Sepsis: which is the target? - Jean François Schved (France)</p> <p>4. Guidelines for the diagnosis and treatment of DIC - Grigoris Gerotziafas (France)</p>
<p>14:00 – 15:00</p>	<p>Lunch Light Lunch-Exhibition and Poster Presentation Science at a Glance Session 2. Moderated Poster Presentations Selection from Submitted Abstracts</p>	

15:00 – 17:00	<p>ADVANCED CLINICAL WORKSHOP. Ischemic Stroke</p> <p>Chairs: Haralampos Milionis (Greece), George Ntaios (Greece)</p> <ol style="list-style-type: none"> 1. Antithrombotic management in medically-treated patients with cryptogenic stroke and patent foramen ovale - Guillaume Turc (France) 2. Intravenous thrombolysis in patients with acute ischemic stroke who are treated with a NOAC. 3. Antithrombotic management in patients with embolic stroke of undetermined source - Robert Hart (Canada) 4. Antithrombotic management in patients with intracranial haemorrhage and an indication for antithrombotic treatment - Roland Veltkamp (Germany) 5. Dual antiplatelet treatment in patients with ischemic stroke: for whom and for how long? - Alexander Tsiskaridze (Georgia) 6. Haemostatic therapies for acute spontaneous intracerebral haemorrhage.- Hanne Christensen (Denmark) 	<p>EMLTD Councilor's and Board's Meeting</p> <p>EMLTD General Assembly</p> <p>STATE OF THE ART SESSION. Thromboimmunology</p> <p>Chairs: Muzaffer Demir (Turkey), Elmina Lefkou (Greece)</p> <ol style="list-style-type: none"> 1. New insight in pathophysiology of antiphospholipid syndrome - Dimitrios Tsakiris (Switzerland) 2. The evolving understanding and management of antiphospholipid syndrome - Beverly Hunt (UK) 3. Hydroxychloroquine for Secondary Prevention of Relapses in Primary Antiphospholipid Syndrome - Arsene Mekinian (France) 4. State of the Art Diagnostic and therapeutic Strategies for Heparin Induced Thrombocytopenia - Ismail Elalamy (France)
17:00 - 17:30	Coffee Break-Exhibition and Poster Presentation Selection from Submitted Abstracts	

17:30 – 19:00

ADVANCED CLINICAL SEMINAR. Management of Pulmonary Embolism: State of the Art 2019

Chairs: [Guy Meyer \(France\)](#)

1. Risk stratification in the acute phase: Advances in concepts, scores, algorithms
2. Reperfusion and circulatory support: Which are the options? Which are the indications?
3. Anticoagulation treatment: The right drug, dose and duration. [Cecilia Beccattini \(Italy\)](#)
4. The pregnant patient with acute PE - [Fionnuala Ni Ainle \(Ireland\)](#)

MEET THE EXPERTS SESSION. PAD, Carotid Artery Disease

Chairs: [Miltiadis Matsagkas \(Greece\)](#)

1. Current evidence in antithrombotic treatment for Carotid artery disease - [Gert De Borst \(The Netherlands\)](#)
2. Antithrombotic treatment during and after carotid interventions - [John Kakisis \(Greece\)](#)
3. The landscape of antithrombotic treatment in PAD after COMPASS.
4. Which PAD patients will probably benefit more from a COMPASS strategy? - [Miltiadis Matsagkas \(Greece\)](#)
5. Antithrombotic Treatment During and After Percutaneous Peripheral Interventions - [Stavros Spiliopoulos \(Greece\)](#)

20:00

Congress Dinner

08:30 – 10:30	<p>WORKSHOP. Awareness and prevention of VTE in European and Middle East countries <i>(Joint Session with ETHA)</i></p> <p>Chairs: Anna Falanga (Italy)</p> <ol style="list-style-type: none"> 1. European Thrombosis and Haemostasis Alliance 2. World Thrombosis Day.
10:30 – 11:00	<p>Coffee Break-Exhibition and Poster Viewing Selection from Submitted Abstracts</p> <p>STATE OF THE ART SESSION - PRESIDENTIAL FAREWELL SYMPOSIUM. Thrombosis and Haemostasis in Childhood and Elderly</p>
11:00 – 13:00	<p>Chairs: Vasileios Voudris (Greece)</p> <ol style="list-style-type: none"> 1. Hemostasis in the Very Young – Gili Kenet (Israel) 2. Antithrombotic treatment in neonates and children - Heleen van Ommen (The Netherlands) 3. Thrombosis risk factors in pediatric cancer 4. Hemostasis and Thrombosis in the Oldest Old - Inna Tzoran (Israel) 5. Safety of Direct Oral Anticoagulants and Vitamin K Antagonists in elderly Patients - Dimitri Richter (Greece) 6. Optimal antiplatelet therapy after an acute coronary syndrome in the elderly - Guido Parodi (Italy)
13:00 – 13:10	INTRODUCING THE 27th INTERNATIONAL CONGRESS ON THROMBOSIS
13:10 – 13:30	AWARD CEREMONY
13:15 – 13:30	Closing Remarks